%0 Journal Article
%T Correlation among  VEGFR3  gene promoter methylation, protein overexpression, and clinical pathology in early gastric cancer
%A Ting-Guo Zhang
%A Xiu-Feng Li
%A Yun-Xiang Zhang
%J SCIE-indexed Journal
%D 2020
%R 10.21037/tcr.2020.03.74
%X Gastric cancer, one of the most prevalent malignant tumors and the third leading cause of cancer mortality worldwide (1), is divided into early gastric cancer (EGC) and advanced gastric cancer. EGC is characterized as gastric cancer with limited aggressiveness within the submucosa, and accounts for major incident gastric cancer in Eastern Asia. Although the 5-year postoperative survival rate of EGC exceeds 90%, a poor prognosis is correlated with lymph node metastasis. Therefore, a better understanding of the role of molecular biomarkers in EGC metastasis is important. Vascular endothelial growth factor receptor 3 (VEGFR3) is a lymphatic endothelial biomarker also found in blood vessels and malignant tumor cells, indicating its involvement in cancer lymphangiogenesis and metastasis (2,3). The occurrence and development of EGC are cumulative processes of multiple factors, stages, and genes. Both genetic and epigenetic mechanisms play important roles in the molecular mechanism of gastric cancer. DNA methylation is one of the most extensively studied epigenetic processes and the methylation degree of certain genes can be an efficient biomarker for early detection, evaluating prognosis and disease recurrence, and even targeted therapy (4-6). Digestive tract cells have a high degree of abnormal methylation and tumor susceptibility (7)
%U http://tcr.amegroups.com/article/view/38159/html